Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4589
- Registration Number
- NCT03703869
- Locations
- 🇨🇴
Investigational Site Number 1700005, Cali, Colombia
🇨🇴Investigational Site Number 1700010, Bogota, Colombia
🇨🇴Investigational Site Number 1700009, Cali, Colombia
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
- Conditions
- Dermatitis Atopic
- Interventions
- Other: Standard of care
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1856
- Registration Number
- NCT03687359
- Locations
- 🇺🇸
C Squared Research Center- Site Number : 8400068, Birmingham, Alabama, United States
🇺🇸Cahaba Dermatology & Skin Health Center- Site Number : 8400046, Birmingham, Alabama, United States
🇺🇸C2 Research Center, LLC- Site Number : 8400071, Montgomery, Alabama, United States
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 908
- Registration Number
- NCT03684642
- Locations
- 🇺🇸
Investigational Site Number 8400009, Los Angeles, California, United States
🇺🇸Investigational Site Number 8400059, Skokie, Illinois, United States
🇺🇸Investigational Site Number 8400061, Boston, Massachusetts, United States
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 5
- Registration Number
- NCT03681158
- Locations
- 🇬🇧
Investigational site number, Nottingham, United Kingdom
Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT03664882
- Locations
- 🇨🇦
Investigational Site Number, Canada, Canada
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Plasmodium Falciparum Infection
- Interventions
- Drug: Ferroquine (SSR97193)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT03660839
- Locations
- 🇧🇯
Investigational Site Number 2040001, Cotonou, Benin
🇧🇫Investigational Site Number 8540002, Banfora, Burkina Faso
🇬🇦Investigational Site Number 2660002, Lambarene, Gabon
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 107
- Registration Number
- NCT03637764
- Locations
- 🇺🇸
Investigational Site Number :8400007, Boston, Massachusetts, United States
🇺🇸Investigational Site Number :8400004, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400002, Houston, Texas, United States
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 393
- Registration Number
- NCT03620747
- Locations
- 🇦🇷
Investigational Site Number :032002, La Plata, Buenos Aires, Argentina
🇦🇷Investigational Site Number :032005, Rosario, Santa Fe, Argentina
🇦🇷Investigational Site Number :032003, Ciudad Autonoma Bs As, Argentina
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 83
- Registration Number
- NCT03600805
- Locations
- 🇵🇹
Investigational Site Number 6200001, Almada, Portugal
🇩🇰Investigational Site Number 2080002, Aarhus C, Denmark
🇫🇷Investigational Site Number 2500006, Pessac, France
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Drug: Sarilumab-matching placeboDrug: Prednisone-matching placebo
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT03600818
- Locations
- 🇺🇸
Investigational Site Number 8400009, Stamford, Connecticut, United States
🇦🇷Investigational Site Number 0320001, Buenos Aires, Argentina
🇷🇺Investigational Site Number 6430001, Moscow, Russian Federation